Will the FDA approved a drug that claims to reduce the number of hours of sleep you need by 2040?

The market indicates a low probability of FDA approval for the sleep-reducing drug by 2040.

The prediction market shows a strong consensus against the FDA approving a drug that claims to reduce sleep needs, with a probability of 82.06% for 'NO'. The Pulse AI also reflects a similar outlook, albeit with slightly higher probabilities for 'YES'. The market appears fairly priced, suggesting balanced sentiment among participants.

• 1 Current market probability for approval is low at 17.94%.
• 2 The Pulse AI indicates a slightly higher probability of 21.44% for approval.
• 3 Market confidence is moderate at 50/100, reflecting uncertainty.
• 4 The time to expiry is substantial at over 120,000 hours, allowing for potential developments.
• 5 The edge of 3.5 suggests that the market is fairly priced based on available information.